Indications |
Oral Painful muscle spasm associated with musculoskeletal conditions Adult: Initially: 1.5 g 4 times daily, reduced according to response after 2-3 days. Maintenance: 2.25-4 g daily in divided doses. Max dose 8 g daily. Elderly: Dose may need to be reduced by half. Intravenous Painful muscle spasm associated with musculoskeletal conditions Adult: 1 g administered by slow inj or infusion at a rate not faster than 300 mg/min. In cases where patients are not able to continue with oral therapy, additional doses of 1 g every 8 hr may be used for up to 3 consecutive days. Max 3 g daily. Elderly: Dose may need to be reduced by half. Intramuscular Painful muscle spasm associated with musculoskeletal conditions Adult: Up to 500 mg into each gluteal region at intervals of 8 hr. In cases where patients are not able to continue with oral therapy, additional doses of 1 g every 8 hr may be used for up to consecutive 3 days. Max 3 g daily. Elderly: Dose may need to be reduced by half. Intravenous Tetanus Adult: Initial total dose: 3 g with 1-2 g via direct inj at a rate of 300 mg/minute and the remainder 1-2 g may be administered via infusion. Repeat infusion of 1-2 g every 6 hr until a nasogastric tube can be inserted. Tablets may be crushed and suspended in water or saline solutions and administered through the nasogastric tube. Total oral dosage of up to 24 g daily may be needed. Child: 15 mg/kg or 500 mg/m2 given by IV inj (suggested rate 180 mg/m2/min). Dose may be repeated every 6 hr if necessary by IV inj or infusion. Max dose 1.8 g/m2 daily for 3 consecutive days. |
Contraindications |
Coma or pre-coma states, brain damage, myasthenia gravis Do not admin parenteral solutions in patients with renal impairment, epilepsy or history of epilepsy. |
Warnings / Precautions |
Renal or hepatic impairment; acidosis. Pregnancy and lactation. May impair ability to drive or operate machinery. Children ≤12 yr. |
Adverse Reactions |
Nausea, anorexia, lassitude, drowsiness, dizziness, restlesness, anxiety, confusion, fever, headache, blurred vision, convulsions; hypersensitivity reactions e.g. rashes, pruritus, urticaria, angiodema. Parenteral: Flushing and a metallic taste; incoordination, diplopia, nystagmus, vertigo; sloughing and thrombophloebitis at the site of inj. Potentially Fatal: Parenteral: Syncope, hypotension, bradycardia, anaphylaxis. |
Overdose Reactions |
Manage with symptomatic and supportive treatment. |
Drug Interactions |
Action potentiated by alcohol and other CNS depressants. May inhibit effect of pyridostigmine, use with caution with anticholinesterase agents. See Below for More methocarbamol Drug Interactions |
Lab Interactions |
May cause colour interference in screening tests for 5-hydroxyindoleacetic acid using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid using the Gitlow method. |
Mechanism of Actions |
Methocarbamol is a centrally acting skeletal muscle relaxant whose precise mode of action is not known. It is said to cause general depression of the central nervous system. Absorption: Rapidly and almost completely absorbed from the GI tract. Peak plasma concentration in 1-2 hr (oral). Distribution: Plasma protein boumd 46-50%. Crosses placenta. Metabolism: Metabolised by dealkylation and hydroxylation. Excretion: Via urine as metabolites and unchanged drug. 1-2 hr (elimination half-life). |
Administration |
May be taken with or without food. (May be taken w/ meals to reduce GI discomfort.) |
Storage Conditions |
Intramuscular: Store at 20-25°C Intravenous: Store at 20-25°C Oral: Store at 20-25°C |
ATC Classification |
M03BA03 - methocarbamol ; Belongs to the class of carbamic esters. Used as centrally-acting muscle relaxants. |
Storage |
Intramuscular: Store at 20-25°C Intravenous: Store at 20-25°C Oral: Store at 20-25°C |
Available As |
|
Methocarbamol
Post Review about Methocarbamol Click here to cancel reply.
Methocarbamol Containing Brands
Methocarbamol is used in following diseases
Drug - Drug Interactions of Methocarbamol
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.